The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...
DelveInsight’s, “Small Lymphocytic Lymphoma Pipeline Insight, 2025” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Small Lymphocytic Lymphoma pipeline landscape.
In this video, Matthew S. Davids, MD, said data from the BRUIN-313 trial supports front-line approval of pirtobrutinib in patients with previously untreated chronic lymphocytic leukemia or small ...
In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when ...
Please provide your email address to receive an email when new articles are posted on . The FDA granted accelerated approval to lisocabtagene maraleucel for treatment of certain patients with relapsed ...
Copiktra (duvelisib) is a type of cancer treatment for certain people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are slow-growing cancers that affect a ...
After reading a book about how Imbruvica was revolutionized for SLL and CLL, I now have a greater appreciation for the drugs I receive. As a patient diagnosed with small lymphocytic lymphoma (SLL), my ...
The 36-month PFS rate for patients with del (17p) and/or TP53 mutation was 87% and for patients without del (17p) and TP53 mutation was 89%. The safety profile of BRUKINSA plus venetoclax was ...
Dr Haumschild drives a discussion surrounding the role of bruton kinase inhibitors for treating CLL and SLL. This is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, ...
The FDA granted accelerated approval to lisocabtagene maraleucel (liso-cel, Breyanzi) for pretreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), drugmaker Bristol Myers ...
As therapy for chronic lymphocytic leukemia (CLL) continues to evolve, 2025 brought research, regulatory news, and expert ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback